Nanomedicine-Based Gene Delivery for the Retina and Posterior Segment Diseases

  • Anita Lalwani
  • Pragna Shelat
  • Jayvadan K. Patel


The eye is an immune-privileged site and is more amenable to genetic therapy. A number of diseases in the posterior segment of the eye have genetic origin. The posterior segment of the eye is difficult to access. But routes to deliver drugs and genes have been worked upon. The genetic therapy ensures long-term treatment of the disease in the eye. The genes that are to be delivered to their proper site can be given through viral and non-viral vectors. Viral vectors offer a number of advantages when it comes to transfection efficiency and gene expression but are associated with immunity issues and cannot be loaded with genes which are more than 5 kb. Over the years non-viral gene vectors are becoming increasingly popular because of their higher gene loading capacity and number of distinct advantages over the viral vectors. But the genes that are to be delivered to the nucleus have to escape a number of degradative mechanisms outside and inside the cell to reach the nucleus. Lipoplexes and polyplexes have been successfully used in the treatment in nonclinical studies, but the clinical applications have still to see the light of the day.


  1. 1.
    Adijanto J, Naash MI. Nanoparticle-based technologies for retinal gene therapy. Eur J Pharm Biopharm. 2015;95:353–67.CrossRefGoogle Scholar
  2. 2.
    Conley SM, Cai X, Naash MI. Non-viral ocular gene therapy: assessment and future directions. Curr Opin Mol Ther. 2008;10(5):456–63.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Edelhauser HF, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010;51(11):5403–20.CrossRefGoogle Scholar
  4. 4.
    Kaur IP, Kakkar S. Nanotherapy for posterior eye diseases. J Control Release. 2014;193:100–12.CrossRefGoogle Scholar
  5. 5.
    Nayerossadat N, Maedeh T, Ali PA. Viral and nonviral delivery systems for gene delivery. Adv Biomed Res. 2012;1:27.CrossRefGoogle Scholar
  6. 6.
    Petit L, Khanna H, Punzo C. Advances in gene therapy for diseases of the eye. Hum Gene Ther. 2016;27(8):563–79.CrossRefGoogle Scholar
  7. 7.
    Pollard H, Remy JS, Loussouarn G, Demolombe S, Behr JP, Escande D. Polyethylenimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells. J Biol Chem. 1998;273:7507–11.CrossRefGoogle Scholar
  8. 8.
    Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview. J Clin Diagn Res. 2015;9(1):GE01–6.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Thakur A, et al. Strategies for ocular siRNA delivery: potential and limitations of non-viral nanocarriers. J Biol Eng. 2012;6:7.CrossRefGoogle Scholar
  10. 10.
    Tros de Ilarduya C, Sun Y, Duzgunes N. Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci. 2010;40(3):159–70.CrossRefGoogle Scholar
  11. 11.
    Zulliger R, Conley SM, Naash MI. Non-viral therapeutic approaches to ocular diseases: an overview and future directions. J Control Release. 2015;219:471–87.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Anita Lalwani
    • 1
  • Pragna Shelat
    • 1
  • Jayvadan K. Patel
    • 2
  1. 1.K. B. Institute of Pharmaceutical Education and ResearchGandhinagarIndia
  2. 2.Nootan Pharmacy College, Faculty of Pharmacy, Sankalchand Patel UniversityVisnagarIndia

Personalised recommendations